January 2017 Options Now Available For Depomed (DEPO)

Investors in Depomed Inc ( DEPO) saw new options become available today, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.

The put contract at the $20.00 strike price has a current bid of $1.50. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $20.00, but will also collect the premium, putting the cost basis of the shares at $18.50 (before broker commissions). To an investor already interested in purchasing shares of DEPO, that could represent an attractive alternative to paying $20.56/share today.

Because the $20.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 59%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 7.50% return on the cash commitment, or 45.62% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for Depomed Inc, and highlighting in green where the $20.00 strike is located relative to that history:

If you liked this article you might like

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

Depomed Focuses on Flagship Drug Rather Than M&A: CEO